Table 1 Baseline demographic and clinical characteristics of patients with Crohn’s disease and ulcerative colitis.
Parameters | Crohn’s disease | Ulcerative colitis | p |
|---|---|---|---|
Number of patients | 21 | 11 | p > 0.05 |
Age in years, mean+SD | 15.2 ± 2.6 | 16.4 ± 2.2 | p > 0.05 |
Gender, male % (n) | 42% (9) | 45% (51) | |
Median time between diagnosis and starting anti-TNF therapy(year) [IQR] | 1.4 [3.6] | 3.0 [3.3] | p > 0.05 |
PCDAI/PUCAI (mean ± SD) | 23.1 ± 14.0 | 27.3 ± 23.0 | |
CRP (mg/l, mean ± SD) | 30.8 ± 43.8 | 14.1 ± 29.3 | p > 0.05 |
Hemoglobin, g/dL, mean+SD | 114.0 ± 19.8 | 129.6 ± 16.6 | p = 0.03 |
Thrombocytes (G/L, mean ± SD) | 451.0 ± 169.4 | 285.3 ± 120.9 | p = 0.005 |
Albumin (g/L, mean+SD) | 38.6 ± 5.8 | 42.4 ± 7.7 | p > 0.05 |
Extent / Location of the disease | |||
L1 | 23.8% (5) | ||
L2 | 33.3% (7) | ||
L3 | 42.8% (9) | ||
L4 | 71.4% (15) | ||
E1 | 0 | ||
E2 | 81.8% (9) | ||
E3 | 0 | ||
E4 | 18.2% (2) | ||
Disease Behavior (B1, B2, B3) | |||
B1 | 14 | ||
B2 | 5 | ||
B3 | 2 | ||
Medical treatment % (n) | |||
5-ASA | 66% (14) | 90 (10) | |
AZA | 80% (17) | 63% (7) | |
MTX | 0 | 9% (1) | |
Antibiotics | 42% (9) | 27% (3) | |
Systemic corticosteroid | 19% (4) | 36% (4) | |
Topical steroid | 14% (3) | 27/% (3) | |
